Back
Full-text
Journal article

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users.

  • Euler Z Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. zeuler@its.jnj.com.
  • VAN DEN Kerkhof TL Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. tom.vdkerkhof@gmail.com.
  • Kouyos RD Institute of Medical Virology, University of Zurich, CH-8057 Zurich, Switzerland. roger.kouyos@uzh.ch.
  • Tully DC Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. tully.damien@mgh.harvard.edu.
  • Allen TM Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. tallen2@partners.org.
  • Trkola A Institute of Medical Virology, University of Zurich, CH-8057 Zurich, Switzerland. trkola.alexandra@virology.uzh.ch.
  • Sanders RW Department of Medical Microbiology, AMC, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. r.w.sanders@amc.uva.nl.
  • Schuitemaker H Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. HSchuite@its.jnj.com.
  • VAN Gils MJ Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands. M.J.vangils@amc.uva.nl.
Show more…
  • 2019-04-28
Published in:
  • Viruses. - 2019
HIV-1
broadly neutralizing antibodies
gender
injecting drug users
transmission route
Antibodies, Neutralizing
CD4 Lymphocyte Count
Drug Users
Female
HIV Antibodies
HIV Infections
HIV-1
Humans
Male
Prevalence
Retrospective Studies
Sex Factors
Substance Abuse, Intravenous
Viral Load
English Understanding the factors involved in the development of broadly neutralizing antibody (bNAb) responses in natural infection can guide vaccine design aimed at eliciting protective bNAb responses. Most of the studies to identify and study the development of bNAb responses have been performed in individuals who had become infected via homo- or heterosexual HIV-1 transmission; however, the prevalence and characteristics of bNAb responses in injecting drug users (IDUs) have been underrepresented. We retrospectively studied the prevalence of bNAb responses in HIV-1 infected individuals in the Amsterdam Cohort, including 50 male and 35 female participants who reported injecting drug use as the only risk factor. Our study revealed a significantly lower prevalence of bNAb responses in females compared to males. Gender, transmission route and CD4+ count at set point, but not viral load, were independently associated with the development of bNAb responses in IDUs. To further explore the influences of gender in the setting of IDU, we also looked into the Swiss 4.5k Screen. There we observed lower bNAb responses in female IDUs as well. These results reveal that the emergence of bNAbs may be dependent on multiple factors, including gender. Therefore, the effect of gender on the development of bNAb responses is a factor that should be taken into account when designing vaccine efficacy trials.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/298937
Statistics
Document views: 20 File downloads:
  • Full-text: 0